News Focus
News Focus
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

Re: jbog post# 9277

Wednesday, 06/27/2012 10:35:46 AM

Wednesday, June 27, 2012 10:35:46 AM

Post# of 20689
The two situations are not analogous. With Copaxone, MNTA has a 50% profit split with NVS regardless of whether other US generics are approved. Hence, a MYL approval would adversely affect NVS/MNTA’s market share and pricing, but it would not change the economics of the NVS-MNTA profit split (as occurred with Lovenox).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”